A RANDOMIZED PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN (TC) VERSUS PACLITAXEL PLUS CISPLATIN (TP) IN STAGE IVB OR RECURRENT CERVICAL CANCER: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0505)

被引：0
|
作者：
Kitagawa, R. [1 ]
Katsumata, N.
Shibata, T.
Nakanishi, T. [2 ]
Nishimura, S. [3 ]
Nishio, S. [4 ]
Takano, M. [5 ]
Satoh, T. [6 ]
Yokota, H. [7 ]
Ochiai, K. [8 ]
Kigawa, J. [9 ]
Kobayashi, H. [10 ]
Kanato, K. [11 ]
Yoshikawa, H. [6 ]
Kamura, T. [4 ]
机构：
[1] NTT Med Ctr Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Gynecol Oncol, Aichi, Japan
[3] Osaka City Gen Hosp, Dept Gynecol Oncol, Osaka, Japan
[4] Kurume Univ, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan
[5] Natl Def Med Coll Hosp, Dept Obstet & Gynecol, Tokorozawa, Saitama, Japan
[6] Univ Tsukuba, Dept Obstet & Gynecol, Tsukuba, Ibaraki 305, Japan
[7] Saitama Canc Ctr, Dept Gynecol Oncol, Saitama, Japan
[8] Jikei Univ, Dept Obstet & Gynecol, Tokyo, Japan
[9] Tottori Univ, Dept Obstet & Gynecol, Yonago, Tottori, Japan
[10] Kyushu Univ, Dept Obstet & Gynecol, Fukuoka 812, Japan
[11] Natl Canc Ctr, Multiinst Clin Trial Support Ctr, JCOG Operat Off, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [31] Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)
    Nomura, H.
    Aoki, D.
    Takahashi, F.
    Katsumata, N.
    Watanabe, Y.
    Konishi, I.
    Jobo, T.
    Hatae, M.
    Hiura, M.
    Yaegashi, N.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 636 - 642
  • [32] A PHASE II TRIAL OF PACLITAXEL PLUS DOXORUBICIN PLUS CARBOPLATIN IN PATIENTS WITH INTERMEDIATE RISK, HIGH RISK, OR RECURRENT ENDOMETRIAL CANCER: A JAPAN ENDOMETRIAL CANCER STUDY GROUP TRIAL
    Kumagai, S.
    Shoji, T.
    Kurachi, H.
    Tabata, T.
    Kigawa, J.
    Nishimura, S.
    Sugiyama, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 312 - 312
  • [33] The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
    Pignata, Sandro
    Scambia, Giovanni
    Lorusso, Domenica
    De Giorgi, Ugo
    Nicoletto, Maria Ornella
    Lauria, Rossella
    Mosconi, Anna Maria
    Sacco, Cosimo
    Omarini, Claudia
    Tagliaferri, Pierosandro
    Ferrandina, Gabriella
    Cinieri, Saverio
    Savarese, Antonella
    Valabrega, Giorgio
    Pisano, Carmela
    Salutari, Vanda
    Raspagliesi, Francesco
    Kopf, Barbara
    Cecere, Sabrina Chiara
    Amadio, Giulia
    Maltese, Giuseppa
    Di Napoli, Marilena
    Greggi, Stefano
    Signoriello, Simona
    Daniele, Gennaro
    Sacco, Alessandra
    Losito, Simona
    Normanno, Nicola
    Perrone, Francesco
    Gallo, Ciro
    Piccirillo, Maria Carmela
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 535 - 540
  • [34] A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
    Dimitrios Bafaloukos
    Helena Linardou
    Gerasimos Aravantinos
    Christos Papadimitriou
    Aristotelis Bamias
    George Fountzilas
    Haralabos P Kalofonos
    Paris Kosmidis
    Eleni Timotheadou
    Thomas Makatsoris
    Epaminondas Samantas
    Evangelos Briasoulis
    Christos Christodoulou
    Pavlos Papakostas
    Dimitrios Pectasides
    Athanasios M Dimopoulos
    BMC Medicine, 8
  • [35] A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
    Bafaloukos, Dimitrios
    Linardou, Helena
    Aravantinos, Gerasimos
    Papadimitriou, Christos
    Bamias, Aristotelis
    Fountzilas, George
    Kalofonos, Haralabos P.
    Kosmidis, Paris
    Timotheadou, Eleni
    Makatsoris, Thomas
    Samantas, Epaminondas
    Briasoulis, Evangelos
    Christodoulou, Christos
    Papakostas, Pavlos
    Pectasides, Dimitrios
    Dimopoulos, Athanasios M.
    BMC MEDICINE, 2010, 8
  • [36] Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
    Aravantinos, G
    Fountzilas, G
    Kosmidis, P
    Dimopoulos, MA
    Stathopoulos, GP
    Pavlidis, N
    Bafaloukos, D
    Papadimitriou, C
    Karpathios, S
    Georgoulias, V
    Papakostas, P
    Kalofonos, HP
    Grimani, E
    Skarlos, DV
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1116 - 1122
  • [37] Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)
    McGuire, WP
    Hoskins, WJ
    Brady, MF
    Kucera, PR
    Partridge, EE
    Look, KY
    ClarkePearson, DL
    Davidson, M
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 40 - 47
  • [38] Randomized phase II trial of carboplatin plus nab-paclitaxel versus cisplatin plus gemcitabine for chemotherapy-naive squamous cell carcinoma: North Japan lung cancer study group 1302
    Kawashima, Yosuke
    Harada, Toshiyuki
    Fujita, Yuka
    Nakagawa, Taku
    Watanabe, Kana
    Morikawa, Naoto
    Takamura, Kei
    Kanazawa, Kenya
    Kuda, Tomoya
    Usui, Kazuhiro
    Sekine, Akimasa
    Inoue, Akira
    Sugawara, Shunichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) : 515 - 522
  • [39] Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study
    Moore, DH
    Blessing, JA
    McQuellon, RP
    Thaler, HT
    Cella, D
    Benda, J
    Miller, DS
    Olt, G
    King, S
    Boggess, JF
    Rocereto, TF
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3113 - 3119
  • [40] Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Wang, Chen
    Hao, Chunfang
    Wang, Xiaorui
    Meng, Wenjin
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345